胰高血糖素100年与未来100年
该综述基于2022年11月在丹麦哥本哈根举行的国际胰高血糖素会议,总结自1922年末发现胰高血糖素以来的基础与临床研究经验,并推测胰高血糖素生物学及基于胰高血糖素的治疗的未来方向。综述聚焦胰高血糖素在糖尿病中的作用,涵盖1型糖尿病中利用其升糖特性治疗低血糖、2型糖尿病中的高胰高血糖素血症、胰高血糖素受体拮抗剂与激动剂及双/三重受体激动剂的开发,以及肝-α细胞轴和「胰高血糖素抵抗」这一新病理生理现象。
要点
- 1型糖尿病中胰高血糖素的升糖特性已被用于治疗性恢复低血糖。
- 2型糖尿病中的高胰高血糖素血症被认为促进高血糖,其机制及在糖尿病发病中的重要性尚待明确。
- 胰高血糖素信号模拟实验推动了胰高血糖素受体拮抗剂、激动剂及双/三重受体激动剂等药物开发。
核心结论
- 胰高血糖素的生理作用已扩展至肝脏蛋白质和脂质代谢,肝-α细胞轴反映其对葡萄糖、氨基酸和脂质代谢的重要性。
- 在糖尿病和脂肪肝病患者中,胰高血糖素的肝脏作用可能部分受损,导致促胰高血糖素氨基酸升高、血脂异常和高胰高血糖素血症,即「胰高血糖素抵抗」。
- 胰高血糖素抵抗中的高胰高血糖素血症可能导致肝葡萄糖生成增加和高血糖。
- 新兴的基于胰高血糖素的疗法对体重减轻和脂肪肝疾病显示出有益影响,重新激发了对其生物学的兴趣以推动进一步药理探索。
研究设计与样本
- 综述基于2022年11月在丹麦哥本哈根举行的题为「与胰高血糖素共度百年及未来百年」的国际胰高血糖素会议。
- 综述总结自胰高血糖素发现以来的基础与临床方面经验,并推测未来方向。
主要发现
- 胰高血糖素于1922年末被发现,由胰腺α细胞分泌,是代谢稳态的重要调节者。
- 1型糖尿病中利用胰高血糖素的升糖特性治疗性恢复低血糖。
- 2型糖尿病中明显的高胰高血糖素血症被提出促进高血糖,引发对其机制及在糖尿病发病中重要性的疑问。
- 胰高血糖素信号模拟实验推动了胰高血糖素受体(GCGR)拮抗剂、GCGR激动剂以及近期结合胰高血糖素与肠促胰岛素激素受体激动作用的双/三重受体激动剂的开发。
- 来自极端胰高血糖素缺乏或分泌过多病例的观察使胰高血糖素的生理作用扩展至肝脏蛋白质和脂质代谢。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The peptide hormone glucagon, discovered in late 1922, is secreted from pancreatic alpha cells and is an essential regulator of metabolic homeostasis. This review summarises experiences since the discovery of glucagon regarding basic and clinical aspects of this hormone and speculations on the future directions for glucagon biology and glucagon-based therapies. The review was based on the international glucagon conference, entitled 'A hundred years with glucagon and a hundred more', held in Copenhagen, Denmark, in November 2022. The scientific and therapeutic focus of glucagon biology has mainly been related to its role in diabetes. In type 1 diabetes, the glucose-raising properties of glucagon have been leveraged to therapeutically restore hypoglycaemia. The hyperglucagonaemia evident in type 2 diabetes has been proposed to contribute to hyperglycaemia, raising questions regarding underlying mechanism and the importance of this in the pathogenesis of diabetes. Mimicry experiments of glucagon signalling have fuelled the development of several pharmacological compounds including glucagon receptor (GCGR) antagonists, GCGR agonists and, more recently, dual and triple receptor agonists combining glucagon and incretin hormone receptor agonism. From these studies and from earlier observations in extreme cases of either glucagon deficiency or excess secretion, the physiological role of glucagon has expanded to also involve hepatic protein and lipid metabolism. The interplay between the pancreas and the liver, known as the liver-alpha cell axis, reflects the importance of glucagon for glucose, amino acid and lipid metabolism. In individuals with diabetes and fatty liver diseases, glucagon's hepatic actions may be partly impaired resulting in elevated levels of glucagonotropic amino acids, dyslipidaemia and hyperglucagonaemia, reflecting a new, so far largely unexplored pathophysiological phenomenon termed 'glucagon resistance'. Importantly, the hyperglucagonaemia as part of glucagon resistance may result in increased hepatic glucose production and hyperglycaemia. Emerging glucagon-based therapies show a beneficial impact on weight loss and fatty liver diseases and this has sparked a renewed interest in glucagon biology to enable further pharmacological pursuits.
引用
- Wewer Albrechtsen NJ, Holst JJ, Cherrington AD, et al. 100 years of glucagon and 100 more. Diabetologia. 2023. PMID: 37367959. doi:10.1007/s00125-023-05947-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。